Abstract
ABSTRACT Long non-coding RNA H19 (H19) is highly expressed in cancers and is considered to highly correlate with the extent of malignant degree. The present study was performed to determine the expression levels of H19 in anaplastic thyroid carcinoma (ATC) tissues and the role of H19 in ATC 8505C cells in vitro and in vivo. Expression of H19 was detected in 19 ATC and 19 normal thyroid tissues by real-time quantitative polymerase chain reaction. Utilizing the siRNA or short hairpin RNA (shRNA) directed against human H19 (H19 siRNA or shRNA H19) depleted H19 in ATC 8505C cells and characterized the outcomes. The results showed that H19 was overexpressed in ATC tissues. Targeting H19 inhibited proliferation, migration, and invasion and induced apoptosis in 8505C cells in vitro and inhibited tumorigenesis and metastasis in vivo. Therefore, the H19 might be an effective target for ATC molecular therapy.
Highlights
Anaplastic thyroid carcinoma (ATC), with a mean survival rate of 4–12 months after diagnosis, is a rare tumor that accounts for 2–5% of all thyroid cancers
Of the 19 ATC tissues, 5 tissues were downregulated and 14 ATC tissues were upregulated compared to Benign thyroid nodules (BTNs)
Highest expression of H19 was found in 8505C cells, so we used 8505C cells for further study
Summary
Anaplastic thyroid carcinoma (ATC), with a mean survival rate of 4–12 months after diagnosis, is a rare tumor that accounts for 2–5% of all thyroid cancers. Clinical evident indicatedthat 50% of ATC patients have had distant metastases at the time of clinical diagnosis, as to the ATC patients who have not had distant metastasis, they will be classified as stage IV by the American Joint Committee on Cancer. Several promising targeted therapies [1,2,3] and multimodal therapy strategies have been explored [4,5,6], there is no definitive evidence to date that these patients can prolong the survival time. Waiting for the advent of new genome-wide approaches, the analysis of the molecular mechanisms involved in the pathogenesis of ATC still remains the only available tool for planning any targeted therapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
